| Sep 23 |
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
|
| Sep 12 |
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock
|
| Sep 11 |
Recursion: AI Is Only As Good As The Data
|
| Sep 8 |
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
|
| Sep 5 |
Recursion: AI Hype Fizzles Amid Hard Clinical Truths
|
| Sep 4 |
Recursion: Path Forward For REC-994 Remains Despite Mixed Response
|
| Sep 4 |
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
|
| Sep 3 |
Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug
|
| Sep 3 |
Recursion posts mid-stage data for lead asset
|
| Sep 3 |
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
|
